CytomX Therapeutics develops Probody⢠therapeutics for the treatment of cancer. Probody therapeutics are fully recombinant masked antibodies that are designed to remain inert in healthy tissue but become activated specifically in the tumor microenvironment. The Probody approach is designed to blunt systemic toxicities associated with antibodies and expand the therapeutic window of these drugs, potentially unlocking new therapeutic targets. The Company is initially focusing this highly innovative platform to discover and develop new immunotherapy and antibody drug conjugate therapies to treat areas of major unmet medical need in oncology. Source
No articles found.
OrthoPediatrics currently markets greater than 30 surgical systems that serve thre...
OrthoPediatrics currently markets greater than ...
Radius is a science-driven fully integrated biopharmaceutical company that is comm...
Radius is a science-driven fully integrated bio...
Evelo develops and sells electric bicycles using a direct-to-consumer distribution...
Evelo develops and sells electric bicycles usin...
Tiziana Life Sciences is a dual-listed (NASDAQ:TLSA, AIM:TILS) clinical stage biot...
Tiziana Life Sciences is a dual-listed (NASDAQ:...
Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical com...
Founded in Lyon, France in 2004, ERYTECH is a c...
Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in th...
Nabriva Therapeutics is a commercial-stage biop...
CTI BioPharma is a biopharmaceutical company focused on the acquisition, developme...
CTI BioPharma is a biopharmaceutical company fo...
Join the National Investor Network and get the latest information with your interests in mind.